Patents Represented by Attorney Beth A. Burrous
-
Patent number: 6682905Abstract: A novel receptor-type protein tyrosine phosphatase (RPTP) protein or glycoprotein and the DNA coding therefor is expressed in a wide variety of mammalian tissues. Included in this family of proteins are human RPTP&agr;, human RPTP&bgr; and human RPTP&ggr;. The RPTP protein or glycoprotein may be produced by recombinant means. Antibodies to the proteins, methods for measuring the quantity of the proteins, methods for screening compounds, such as drugs, which can bind to the proteins and inhibit or stimulate their activity, are provided.Type: GrantFiled: March 29, 1999Date of Patent: January 27, 2004Assignee: New York UniversityInventors: Joseph Schlessinger, Jan M Sap
-
Patent number: 6682921Abstract: Crystals of the tyrosine kinase domain of cytoplasmic tyrosine kinases and receptor tyrosine kinases that undergo ligand-mediated receptor dimerization are provided. In particular, crystals of a mutant of the tyrosine kinase domain of fibroblast growth factor receptor 1 (FLGK), alone and in complex with a non-hydrolyzable adenosine triphosphate analogue, are provided. Also provided are the high resolution three dimensional structures of crystalline FLGK, both alone and in co-complex with the adenosine triphosphate analogue, as determined by X-ray diffraction.Type: GrantFiled: September 18, 2000Date of Patent: January 27, 2004Assignee: New York UniversityInventors: Moosa Mohammadi, Joseph Schlessinger, Stevan R. Hubbard
-
Patent number: 6680170Abstract: The present invention relates to the nucleic acid molecules encoding an STE20-related family of novel protein kinases, ZC1, ZC2, ZC3, ZC4, STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, KHS2, SULU1, SULU3, GEK2, PAK4 and PAK5, segments and domains thereof, as well as various methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Mammalian nucleic acid molecules encoding these kinases are particularly disclosed, and more specifically human sources of these nucleic acids are disclosed.Type: GrantFiled: April 13, 1999Date of Patent: January 20, 2004Assignee: Sugen, Inc.Inventors: Gregory Plowman, Ricardo Martinez, David Whyte
-
Patent number: 6680335Abstract: The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds. The invention also relates to methods of modulating the function of protein kinases using indolinone compounds and methods of treating diseases by modulating the function of protein kinases and related signal transduction pathways.Type: GrantFiled: December 13, 2001Date of Patent: January 20, 2004Assignee: Sugen, Inc.Inventor: Peng Cho Tang
-
Patent number: 6677368Abstract: The present invention relates to 4-arylindolinones, as well as pharmaceutical compositions thereof, capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. The present invention also relates to methods for treating protein kinase related disorders.Type: GrantFiled: December 20, 2001Date of Patent: January 13, 2004Assignee: Sugen, Inc.Inventors: Jingrong Cui, Ruofei Zhang, Hong Shen, Ji Yu Chu, Fang-Jie Zhang, Marcel Koenig, Steven Huy Do, Xiaoyuan Li, Chung Chen Wei, Peng Cho Tang
-
Patent number: 6660763Abstract: The present invention relates to a class of indolylquinone compounds that inhibit GRB-2 adaptor protein function, pharmaceutical compositions comprising these compounds, and methods for ameliorating the symptoms of cell proliferative disorders associated with GRB-2 adaptor protein function using these compounds. The present invention further relates to methods for treating insulin-related disorders, such as diabetes, insulin resistance, insulin deficiency and insulin allergy, and for ameliorating the symptoms of insulin-related disorders, using certain indolylquinone compounds and pharmaceutical compositions thereof. The present invention also relates to novel synthetic methods for the preparation of mono- and bis-indolylquinone compounds.Type: GrantFiled: May 4, 2000Date of Patent: December 9, 2003Assignee: Sugen, Inc.Inventors: Peng Cho Tang, Gerald McMahon, G. Davis Harris, Jr., Ken Lipson
-
Patent number: 6656940Abstract: The present invention relates to tricyclic quinoxaline compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein tyrosine kinases and therefore should be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.Type: GrantFiled: November 9, 2001Date of Patent: December 2, 2003Assignee: Sugen, Inc.Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
-
Patent number: 6656716Abstract: The present invention related to the novel human kinase polypeptides STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU2, SULU3, GEK2, PAK4, and PAK5, nucleotide sequences encoding the novel kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions.Type: GrantFiled: October 16, 2000Date of Patent: December 2, 2003Assignee: Sugen, Inc.Inventors: Gregory Plowman, Ricardo Martinez, David Whyte
-
Patent number: 6649635Abstract: The present invention relates to novel heteroaryl-carboxamides which modulate the activity of protein tyrosine kinases and therefore are expected to be useful in the treatment of abnormal protein tyrosine kinase activity driven disorders including cancer.Type: GrantFiled: September 7, 2001Date of Patent: November 18, 2003Assignee: Sugen, Inc.Inventors: Gerald McMahon, Peng Cho Tang, Laura Kay Shawver, Klaus Peter Hirth
-
Patent number: 6642251Abstract: The present invention relates to novel geometrically restricted 2-indolinones and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.Type: GrantFiled: January 15, 2003Date of Patent: November 4, 2003Assignee: Sugen, Inc.Inventors: Peng Cho Tang, Todd Anthony Miller, Li Sun, Ngoc My Tran, Asaad Nematalla, Anh Thi Nguyen
-
Patent number: 6642232Abstract: The present invention relates to certain 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives that inhibit kinases, in particular VEGFR and/or PDGFR kinases. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.Type: GrantFiled: October 10, 2002Date of Patent: November 4, 2003Assignee: Sugen, Inc.Inventors: Matthew Mattson, Tomas Vojkovsky, Congxin Liang, Peng Cho Tang, Huiping Guan
-
Patent number: 6635640Abstract: The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases (“PKs”), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.Type: GrantFiled: June 29, 2001Date of Patent: October 21, 2003Assignee: Sugen, Inc.Inventors: Peng Cho Tang, Chung Chen Wei, Ping Huang, Jingrong Cui
-
Patent number: 6630318Abstract: The present invention relates to compositions and methods for the prevention, prognostic evaluation, and treatment of oncogenic disorders, especially breast cancer, wherein a protein tyrosine kinase capable of complexing with a member of the SH2- and/or SH3-containing family of adaptor proteins is involved. In a preferred embodiment of the invention, the protein tyrosine kinase is the receptor protein tyrosine kinase HER2, and the adaptor protein is GRB, so that the protein tyrosine kinase/adaptor protein complex is a HER2/GRB-7 complex.Type: GrantFiled: December 10, 1999Date of Patent: October 7, 2003Assignee: New York UniversityInventor: Benjamin Lewis Margolis
-
Patent number: 6613557Abstract: A method of providing papillomavirus like articles which may be used for diagnostic purposes or for incorporation in a vaccine for use in relation to infections causd by papillomavirus. The method includes an initial step of constructing one or more recombinant DNA molecules which each encode papillomavirus L1 protein or a combination of papillomavirus L1 protein and papillomavirus L2 protein followed by a further step of transfecting a suitable host cell with one or more of the recombinant DNA molecules so that virus like particles (VLPs) are produced within the cell after expression of the L1 or combination of L1 and L2 proteins. The VLPs are also claimed per se as well as vaccines incorporating the VLPs.Type: GrantFiled: September 7, 2001Date of Patent: September 2, 2003Assignees: The University of Queensland, CSL LimitedInventors: Ian Frazer, Jian Zhou
-
Patent number: 6610688Abstract: This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Particular 4-substituted 7-aza-indolin-2-ones disclosed herein are of Formula 1 and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, X, Y, and Z are defined herein. The invention further relates to pharmaceutical compositions and dosage forms comprising compounds of Formula 1 and to methods of their use for the treatment and/or prevention of diseases such as, but not limited to, cancer.Type: GrantFiled: December 21, 2000Date of Patent: August 26, 2003Assignee: Sugen, Inc.Inventors: Congxin Liang, Li Sun, Chung Chen Wei, Peng Cho Tang, Gerald McMahon, Klaus Peter Hirth, Jingrong Cui
-
Patent number: 6607729Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: GrantFiled: March 5, 2001Date of Patent: August 19, 2003Assignee: The University of QueenslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 6599902Abstract: The present invention relates to certain 5-aralkylsulfonyl-3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives that inhibit kinases, in particular met kinase. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.Type: GrantFiled: May 30, 2002Date of Patent: July 29, 2003Assignee: Sugen, Inc.Inventors: Jingrong Cui, John Ramphal, Congxin Liang, Connie Li Sun, Chung Chen Wei, Peng Cho Tang
-
Patent number: 6596772Abstract: The invention relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are related to cellular signal transduction, in particular, protein tyrosine phosphatase, and therefore are expected to be useful in the prevention and treatment of disorders associated with abnormal protein tyrosine enzyme related cellular signal transduction such as cancer, diabetes, immuno-modulation, neurologic degenerative diseases, osteoporosis and infectious diseases. The invention also relates to the use of compounds containing fluoromethyl sulfonyl groups as phosphate mimics. These mimics may be used to inhibit, regulate or modulate the activity of a phosphate binding protein in a cell.Type: GrantFiled: August 25, 2000Date of Patent: July 22, 2003Assignee: Sugen, Inc.Inventors: Ping Huang, Chung Chen Wei, Peng Cho Tang, Chris Liang, John Ramphal, Bahija Jallal, John Biltz, Sharon Li, Matt Mattson, Gerald McMahon, Marcel Koenig
-
Patent number: 6596878Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity HER2 or EGFR.Type: GrantFiled: September 18, 2001Date of Patent: July 22, 2003Assignees: Yissum Research & Development Company of the Hebrew University, Sugen, Inc.Inventors: Hui Chen, Aviv Gazit, Alexander Levitzki, Klaus Peter Hirth, Elaina Mann, Laura K. Shawver, Jianming Tsai, Peng Cho Tang
-
Patent number: 6579972Abstract: The present invention relates, in general, to an extracellular signal regulated kinase, ERK-5.Type: GrantFiled: September 9, 1999Date of Patent: June 17, 2003Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften, e.V.Inventors: Cornelia Lechner, Niels Peter Møller, Axel Ullrich